Cancer type | MSI-H (%) | Cancer type | MSI-H (%) | Cancer type | MSI-H (%) | Cancer type | MSI-H (%) |
|---|
UCEC | 17.00–31.37 | BRCA | 0.00–1.53 | PRAD | 0.60–3.00 | KICH | 0.00 |
COAD | 6.00–19.72 | KIRC | 1.47 | LUAD | 0.53–1.00 | KIRP | 0.00 |
STAD | 9.00–19.09 | OV | 1.37–2.00 | BLCA | 0.49 | LAML | 0.00 |
READ | 5.73 | CHOL | 1.35–3.00 | NBL | 0.45 | NPC | 0.00 |
ACC | 4.35 | THYM | 0.81 | LGG | 0.39 | PAAD | 0–2.00 |
UCS | 3.00–3.51 | LIHC | 0.80–3.00 | CLL | 0.30 | PCPG | 0.00 |
CESC | 2.62–4.00 | HNSC | 0.78 | GBM | 0.25 | TGCT | 0.00 |
WT | 2.44 | SARC | 0.78 | AML | 0.00 | THCA | 0.00–3.00 |
MESO | 2.41 | SKCM | 0.00–0.64 | CTCL | 0.00 | UVM | 0.00–2.00 |
ESCA | 1.63 | LUSC | 0.60 | DLBC | 0.00 | Â | Â |
- Abbreviations: UCEC uterine corpus endometrial carcinoma, COAD colon adenocarcinoma, STAD stomach adenocarcinoma, READ rectal adenocarcinoma, ACC adrenocortical carcinoma, UCS uterine carcinosarcoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, WT Wilms tumor, MESO mesothelioma, ESCA esophageal carcinoma, BRCA breast carcinoma, KIRC kidney renal clear cell carcinoma, OV ovarian serous cystadenocarcinoma, CHOL cholangiocarcinoma, THYM thymoma, LIHC liver hepatocellular carcinoma, HNSC head and neck squamous cell carcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, LUSC lung squamous cell carcinoma, PRAD prostate adenocarcinoma, LUAD lung adenocarcinoma, BLCA bladder carcinoma, NBL pediatric neuroblastoma, LGG lower-grade glioma, CLL chronic lymphocytic leukemia, GBM glioblastoma multiforme, AML pediatric acute myeloid leukemia, CTCL cutaneous T cell lymphoma, DLBC diffuse large B cell lymphoma, KICH kidney chromophobe, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukemia, NPC nasopharyngeal carcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, TGCT testicular germ cell tumor, THCA thyroid carcinoma, UVM uveal melanoma
